Infant mice with glutaric acidaemia type I have increased vulnerability to 3-nitropropionic acid toxicity
Glutaric acidaemia type I (GA I) is an inborn error of metabolism caused by a deficiency of glutaryl-CoA dehydrogenase (GCDH) and is characterized clinically by striatal degeneration that almost always occurs in early childhood. A murine knockout model of GA I has the organic aciduria seen in the human disorder, but this model does not develop striatal degeneration spontaneously. 3-Nitropropionic acid (3NP), a succinic dehydrogenase inhibitor with specificity for the striatum, was investigated as a potential initiator of striatal degeneration in GCDH-deficient mice. This study shows that GCDH-deficient mouse pups are more susceptible to 3NP than their wild-type littermates, and that all mouse pups are more sensitive to 3NP as infants than as adolescents and adults. Increased sensitivity to 3NP early in life may model the developmental window for the striatal damage observed in human GA I.
- GA I
glutaric acidaemia type I
Unable to display preview. Download preview PDF.
- Alexi T, Hughes PE, Faull RLM, William CE (1998b) 3-Nitropropionic acid’s lethal triplet: cooperative pathways of neurodegeneration. NeuroReport 9, R57–R64.Google Scholar
- Goodman SI, Biery BJ (1996) Glutaric acidemia (type 1) Ment Retard Dev Disabil Res Rev 2: 155–159.Google Scholar
- Goodman SI, Frerman FE (2001) Organic acidemias due to defects in lysine oxidation: 2-ketoadipic acidemia and glutaric acidemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 2195–2204.Google Scholar
- Goodman SI, Kohlhoff JG (1975) Glutaric aciduria: inherited deficiency of glutaryl- CoA dehydrogenase activity. Biochem Med 13, 138–40.Google Scholar
- Haworth JC, Booth FA, Chudley AE, et al (1991) Phenotypic variability in glutaric aciduria type 1: report of fourteen cases in five Canadian Indian kindreds. J Pediatr 118: 52–58.Google Scholar
- Herlenius E, Lagercrantz H (2004) Development of neurotransmitter systems during critical periods. Exp Neurol 190, s8–s21.Google Scholar
- Virmani A, Gaetani F, Binienda Z (2005) Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: metabolic inhibitors MPTP, methamphetamine. Ann NY Acad Sci 1 053: 183–191.Google Scholar